Amanote Research
Register
Sign In
Trend of Cost of Newer Glucose-Lowering Agents in Patients With Type 2 Diabetes Mellitus: Evidence From a Medical System in Taiwan
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.07.281
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
September 1, 2018
Authors
S Wu
K Chang
Y Chan
Publisher
Elsevier BV
Related search
The Cost-Effectiveness of Dulaglutide Versus Liraglutide in Patients With Type 2 Diabetes Mellitus in Taiwan
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Lowering Low-Density Lipoprotein Cholesterol Levels in Patients With Type 2 Diabetes Mellitus
International Journal of General Medicine
Medicine
Effects of Intensive Glucose Lowering in Type 2 Diabetes
Yearbook of Endocrinology
Blood Glucose-Lowering Therapy in Adults With Type 2 Diabetes
Nurse Prescribing
Seasonal Variation in Severe Glucose-Lowering Drug-Induced Hypoglycemia in Patients With Type 2 Diabetes
Internal Medicine
Internal Medicine
Medicine
Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-Of-The-Art Review
Mayo Clinic Proceedings
Medicine
Evaluation Approach Can Significantly Influence Oral Glucose-Lowering Drugs Total Mortality Risks in Retrospective Cohorts of Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews
Endocrinology
Metabolism
Diabetes
Pdb52 - Annual Cost of Acute Myocardial Infarction in Patients With Type 2 Diabetes Mellitus in Turkey
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Detection of OSA in Patients With Type 2 Diabetes Mellitus
International Journal of Diabetes & Metabolic Disorders
